Multiresistant bacteria and current therapy - the economical side of the story
Severe infections with multiresistant bacteria (MRB) are a medical challenge and a financial burden for hospitals. The adequate antibiotic therapy is a key issue in multiresistant bacteria management. Several major cost drivers have been identified. Remarkably drug acquisition costs are not necessar...
| Main Author: | |
|---|---|
| Format: | Online |
| Language: | English |
| Published: |
BioMed Central
2010
|
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3352106/ |